COMING SOON: Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA

Expert oncologist Alex Spira, MD, PhD, FACP, shares his excitement for an upcoming program centered on the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.

Related Keywords

,Lazertinib Versus Osimertinib ,Mutated Advanced ,Primary Results From ,Nsclc ,Non Small Cell Lung Cancer ,Advanced Nsclc ,Metastatic Nsclc ,Mnsclc ,Mariposa Trial ,Mariposa Study ,Egfr Mutated ,Egfr Mutant ,Amivantamab ,Lazertinib ,Osimertinib ,Combination Therapy ,Novel Therapy ,Egfr Tki ,Tyrosine Kinase Inhibitors ,Met Inhibitor ,Chrysalis Study ,Chrysalis Trial ,Exon 20 ,L858r ,Egfr L858r ,Efficacy Data ,Overall Survival ,Progression Free Survival ,Pfs Data ,Cns Disease ,Brain Metastases ,Pfs2 ,Safety Data ,Adverse Events ,Vte Events ,